Literature DB >> 33590278

Propensity-score analysis comparing perioperative and functional outcomes between XPS 180 W-photovaporization and GreenLight laser enucleation of the prostate: reasons to discard vaporization and move to enucleation.

Anis Gasmi1, Zine-Eddine Khene1, Sonia Guérin1, Karim Bensalah1, Benoit Peyronnet1, Romain Mathieu1, Morgan Roupret2, Enrique Rijo3, Benjamin Pradère1, Vincent Misrai4.   

Abstract

PURPOSE: To compare the perioperative and functional outcomes between 180_W XPS GreenLight photoselective vaporization (PVP) and 532-nm GreenLight laser enucleation of the prostate (GreenLEP) in the surgical management of benign prostatic obstruction (BPO).
METHODS: Retrospective review of a prospectively maintained international database of patients managed with GreenLight laser surgery (PVP or GreenLEP) was performed. To adjust for potential baseline confounders, propensity-score matching (PSM) was applied at a ratio of 1:1 to compare the perioperative and functional outcomes between the groups.
RESULTS: A total of 2,420 patients were included. 1,491 (61.6%) underwent PVP and 929 (38.4%) underwent GreenLEP. Before PSM analysis, patients in the vaporization group were older (p < 0.001), had a lower PSA and prostate volume at baseline (p < 0.001). Using estimated propensity scores, 78 patients in the PVP group were matched 1:1 to the patients in the GreenLEP group. The incidence of overall postoperative complications was comparable between the two groups (19 vs. 16%, p = 0.06). However, after PSM, PVP was found to be associated with a higher rate of overall complications (33 vs. 11%, p = 0.001). At 3 months and at last follow-up the I-PSS, Qmax and PSA had similarly decreased in the two groups with a greater improvement in the GreenLEP group (all p < 0.05).
CONCLUSIONS: PVP and GreenLEP are two efficient and safe techniques for treating BPO. However, PVP was associated with longer operative time and higher risk of reoperation on a midterm follow-up compared to GreenLEP.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.

Entities:  

Keywords:  Enucleation; GreenLEP; Laser prostatectomy; Laser therapy; Prostate; Prostatic hyperplasia

Year:  2021        PMID: 33590278     DOI: 10.1007/s00345-021-03590-z

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  22 in total

Review 1.  A systematic review of holmium laser prostatectomy for benign prostatic hyperplasia.

Authors:  Rebecca Tooher; Peter Sutherland; Anthony Costello; Peter Gilling; Guy Rees; Guy Maddern
Journal:  J Urol       Date:  2004-05       Impact factor: 7.450

2.  GreenLight HPS 120-W laser vaporization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia: a randomized clinical trial with midterm follow-up.

Authors:  Abdulla Al-Ansari; Nagy Younes; Venkataramana Pai Sampige; Khalid Al-Rumaihi; Ardalan Ghafouri; Tawiz Gul; Ahmed A Shokeir
Journal:  Eur Urol       Date:  2010-05-27       Impact factor: 20.096

3.  The surgical learning curve for endoscopic GreenLight™ laser enucleation of the prostate: an international multicentre study.

Authors:  Zine-Eddine Khene; Benoit Peyronnet; Sébastien Vincendeau; Romain Huet; Anis Gasmi; Benjamin Pradere; Marie Pasquie; Shahin Tabatabaei; Giovanni Ferrari; Morgan Roupret; Romain Mathieu; Enrique Rijo; Fernando Gomez-Sancha; Vincent Misrai
Journal:  BJU Int       Date:  2019-09-17       Impact factor: 5.588

4.  Holmium laser enucleation (HoLEP) and photoselective vaporisation of the prostate (PVP) for patients with benign prostatic hyperplasia (BPH) and chronic urinary retention.

Authors:  Christopher D Jaeger; Christopher R Mitchell; Lance A Mynderse; Amy E Krambeck
Journal:  BJU Int       Date:  2015-02       Impact factor: 5.588

5.  A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study.

Authors:  James A Thomas; Andrea Tubaro; Neil Barber; Frank d'Ancona; Gordon Muir; Ulrich Witzsch; Marc-Oliver Grimm; Joan Benejam; Jens-Uwe Stolzenburg; Antony Riddick; Sascha Pahernik; Herman Roelink; Filip Ameye; Christian Saussine; Franck Bruyère; Wolfgang Loidl; Tim Larner; Nirjan-Kumar Gogoi; Richard Hindley; Rolf Muschter; Andrew Thorpe; Nitin Shrotri; Stuart Graham; Moritz Hamann; Kurt Miller; Martin Schostak; Carlos Capitán; Helmut Knispel; Alexander Bachmann
Journal:  Eur Urol       Date:  2015-08-15       Impact factor: 20.096

Review 6.  A Systematic Review and Meta-analysis of Functional Outcomes and Complications Following Transurethral Procedures for Lower Urinary Tract Symptoms Resulting from Benign Prostatic Obstruction: An Update.

Authors:  Jean-Nicolas Cornu; Sascha Ahyai; Alexander Bachmann; Jean de la Rosette; Peter Gilling; Christian Gratzke; Kevin McVary; Giacomo Novara; Henry Woo; Stephan Madersbacher
Journal:  Eur Urol       Date:  2014-06-25       Impact factor: 20.096

7.  Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial.

Authors:  Rainer M Kuntz; Karin Lehrich; Sascha A Ahyai
Journal:  Eur Urol       Date:  2007-08-28       Impact factor: 20.096

8.  Comparison Between Thulium Laser VapoEnucleation and GreenLight Laser Photoselective Vaporization of the Prostate in Real-Life Setting: Propensity Score Analysis.

Authors:  Daniele Castellani; Luca Cindolo; Cosimo De Nunzio; Mirko Di Rosa; Francesco Greco; Luca Gasparri; Vincenzo Maria Altieri; Luigi Schips; Andrea Tubaro; Marco Dellabella
Journal:  Urology       Date:  2018-09-14       Impact factor: 2.649

9.  Impact of surgical wait times during summer months on the oncological outcomes following robotic-assisted radical prostatectomy: 10 years' experience from a large Canadian academic center.

Authors:  Ahmed S Zakaria; Félix Couture; David-Dan Nguyen; Côme Tholomier; Hanna Shahine; Franziska Stolzenbach; Malek Meskawi; Pierre I Karakiewicz; Assaad El-Hakim; Kevin C Zorn
Journal:  World J Urol       Date:  2020-10-27       Impact factor: 4.226

Review 10.  What is a disease? What is the disease clinical benign prostatic hyperplasia (BPH)?

Authors:  Keong Tatt Foo
Journal:  World J Urol       Date:  2019-02-25       Impact factor: 4.226

View more
  1 in total

1.  TURPxit or not: contemporary management options for benign prostatic obstruction.

Authors:  Thomas R W Herrmann; Vincent Misrai; Fernando Gómez Sancha; Thorsten Bach
Journal:  World J Urol       Date:  2021-07       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.